Active Ingredient History
Alpelisib (BYL719) is a PI3Kα-selective inhibitor. PI3K-AKT-mTOR pathway is frequently activated in cancer, therefore investigational PI3K inhibitor alpelisib is considered to be effective as an anticancer agent and has been in clinical development by Novartis. Alpelisib have demonstrated activity in preclinical models of solid tumors and had favorable tolerability profiles, with the most common adverse events consistent with “on-target” inhibition of PI3K in early clinical studies. There are ongoing clinical trials of alpelisib in a range of cancer types, including breast cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma, lymphoma, and glioblastoma multiforme. Combination therapy with other chemo therapeutics may be preferable. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Growth and Development (approved 2022)
Androgens (Phase 1)
Arteriovenous Malformations (Phase 2)
Biomarkers (Phase 1)
Breast Neoplasms (Phase 3)
Carcinoma, Squamous Cell (Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
Drugs, Investigational (Phase 1)
Dyslipidemias (Phase 1)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 1)
Esophageal Squamous Cell Carcinoma (Phase 1)
Genetic Diseases, Inborn (Phase 2)
Growth and Development (Phase 2)
Head and Neck Neoplasms (Phase 2)
Human Papillomavirus Viruses (Phase 1)
Hyperinsulinism (Phase 1)
Insulin Resistance (Phase 1)
Kidney Neoplasms (Phase 1)
Leukemia, Myeloid, Acute (Phase 1/Phase 2)
Liver Diseases (Phase 1)
Lung Neoplasms (Phase 2)
Lymphangioma (Phase 2)
Lymphangioma, Cystic (Phase 2)
Lymphatic Diseases (Phase 2/Phase 3)
Megalencephaly (Phase 2)
Melanoma (Phase 1)
Meningioma (Phase 1)
Multiple Myeloma (Phase 1/Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 1/Phase 2)
Neoplasms (Phase 2)
Oropharyngeal Neoplasms (Phase 1/Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 2)
Papilloma (Phase 1)
Papillomavirus Infections (Phase 2)
Prostatic Neoplasms (Phase 2)
ras Proteins (Phase 2)
Rectal Neoplasms (Phase 1)
Sarcoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 1/Phase 2)
Triple Negative Breast Neoplasms (Phase 3)
Vascular Diseases (Phase 2)
Vascular Malformations (Phase 2)
Venous Cutdown (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
